0001209191-22-035067.txt : 20220608
0001209191-22-035067.hdr.sgml : 20220608
20220608164931
ACCESSION NUMBER: 0001209191-22-035067
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220606
FILED AS OF DATE: 20220608
DATE AS OF CHANGE: 20220608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ozawa Clare
CENTRAL INDEX KEY: 0001746742
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39112
FILM NUMBER: 221004027
BUSINESS ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: (415) 801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
FORMER NAME:
FORMER CONFORMED NAME: Clare Ozawa
DATE OF NAME CHANGE: 20180716
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oyster Point Pharma, Inc.
CENTRAL INDEX KEY: 0001720725
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 811030955
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: (609) 382-9032
MAIL ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-06
0
0001720725
Oyster Point Pharma, Inc.
OYST
0001746742
Ozawa Clare
C/O OYSTER POINT PHARMA, INC.
202 CARNEGIE CENTER, SUITE 109
PRINCETON
NJ
08540
1
0
0
0
Common Stock
2022-06-06
4
A
0
3573
0.00
A
14637
D
Common Stock
414607
I
See Footnotes
Common Stock
2465
I
See Footnotes
Common Stock
2236888
I
See Footnotes
Common Stock
1003658
I
See Footnotes
Stock Option (Right to Buy)
3.63
2022-06-06
4
A
0
5359
0.00
A
2032-06-05
Common Stock
5359
5359
D
Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
The shares underlying the RSU will vest on June 6, 2023, but will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date.
Shares held by Versant Venture Capital IV, L.P. ("Versant IV"). The Reporting Person disclaims beneficial ownership of the shares held by Versant IV, except to the extent of her pecuniary interest therein.
Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV"). The Reporting Person disclaims beneficial ownership of the shares held by Versant Side Fund IV, except to the extent of her pecuniary interest therein.
Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the sole general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") and Versant Ventures VI GP is the sole general partner of Versant VI. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant VI, except to the extent of their respective pecuniary interests therein.
Shares held by Versant Vantage I, L.P. ("Versant Vantage"). Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("Versant Vantage I GP") and Versant Vantage I GP is the sole general Partner of Versant Vantage. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage. Each of Versant Vantage I GP-GP, Versant Vantage I GP, and the Reporting Person disclaims beneficial ownership of the shares held by Versant Vantage, except to the extent of their respective pecuniary interests therein.
The shares underlying the option vest as to one-twelfth (1/12th) of the shares on July 6, 2022 and monthly thereafter on the same day of the month as the grant date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date.
/s/ Robin L. Praeger, Attorney-in-Fact for Clare Ozawa
2022-06-08